• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾衰竭合并失代偿期肝硬化继发大量腹水患者的腹水超滤血液透析替代治疗

Hemodialysis alternative with ascites ultrafiltration for an end-stage renal failure patient associated with tense ascites secondary to decompensated liver cirrhosis.

作者信息

Hwang J C, Chen J A, Fung H Y

机构信息

Division of Nephrology, Chi-Mei Foundation Hospital, Tainan, Taiwan.

出版信息

Am J Kidney Dis. 1996 Dec;28(6):899-903. doi: 10.1016/s0272-6386(96)90391-1.

DOI:10.1016/s0272-6386(96)90391-1
PMID:8957043
Abstract

Patients with end-stage renal disease combined with tense ascites caused by decompensated liver cirrhosis are sometimes encountered in a hemodialysis center. A big problem for the management of these patients is the tendency of hypotension during ultrafiltration. Subsequent fluid accumulation, especially in the abdominal cavity, causes breathing difficulty and abdominal discomfort. We present a new technique, ascites ultrafiltration, to solve this problem. Using the same equipment as for ordinary hemodialysis, and incurring the same cost, we removed directly approximately 8 L of ascites fluid during each nearly 4-hour session. No hemodynamic instability was noted. We proved this technique to be an effective and safe alternative method for this group of patients.

摘要

血液透析中心有时会遇到终末期肾病合并失代偿期肝硬化所致大量腹水的患者。这类患者管理中的一个大问题是超滤过程中出现低血压的倾向。随后的液体蓄积,尤其是腹腔内的液体蓄积,会导致呼吸困难和腹部不适。我们提出一种新技术——腹水超滤,以解决这一问题。使用与普通血液透析相同的设备,成本相同,我们在每次近4小时的治疗过程中直接清除了约8升腹水。未观察到血流动力学不稳定情况。我们证明了该技术是这类患者一种有效且安全的替代方法。

相似文献

1
Hemodialysis alternative with ascites ultrafiltration for an end-stage renal failure patient associated with tense ascites secondary to decompensated liver cirrhosis.终末期肾衰竭合并失代偿期肝硬化继发大量腹水患者的腹水超滤血液透析替代治疗
Am J Kidney Dis. 1996 Dec;28(6):899-903. doi: 10.1016/s0272-6386(96)90391-1.
2
Continuous arterio-venous ultrafiltration in cirrhotic patients with ascites or renal failure.肝硬化腹水或肾衰竭患者的持续动静脉超滤
Int J Artif Organs. 1986 Jul;9(4):253-6.
3
Management of refractory ascites by using a peritoneal dialysis system with extracorporeal ultrafiltration by hemodialysis dialyzer.采用腹膜透析系统联合血液透析透析器进行体外超滤治疗难治性腹水。
Perit Dial Int. 2003 Dec;23 Suppl 2:S170-4.
4
Peritoneal dialysis in end-stage renal disease patients with preexisting chronic liver disease and ascites.终末期肾病合并慢性肝病及腹水患者的腹膜透析
Am J Med. 1992 Jul;93(1):35-40. doi: 10.1016/0002-9343(92)90677-4.
5
Dialytic ultrafiltration by hemofilter in treatment of patients with refractory ascites and renal insufficiency.血液滤过进行透析超滤治疗难治性腹水合并肾功能不全患者。
Am J Gastroenterol. 1987 Jul;82(7):665-8.
6
Ascites reinfusion dialysis of refractory ascites as a bridge to kidney and liver transplantation in a patient on hemodialysis.难治性腹水的腹水再输注透析作为血液透析患者肾移植和肝移植的桥梁。
Korean J Intern Med. 2017 Mar;32(2):363-364. doi: 10.3904/kjim.2015.094. Epub 2016 Jan 19.
7
Peritoneo-venous shunting in patients with cirrhotic ascites and end-stage renal failure.肝硬化腹水合并终末期肾衰竭患者的腹腔-静脉分流术。
Am J Kidney Dis. 1985 Sep;6(3):185-7. doi: 10.1016/s0272-6386(85)80025-1.
8
Ascites reinfusion dialysis (ARD) for renal failure with refractory ascites.
Clin Nephrol. 2004 Nov;62(5):374-9. doi: 10.5414/cnp62374.
9
Water immersion in an anuric cirrhotic patient.无尿肝硬化患者的水浸情况。
Nephron. 1986;43(2):144-7. doi: 10.1159/000183814.
10
Renal replacement therapy in end-stage renal disease patients with chronic liver disease and ascites: role of peritoneal dialysis.终末期肾病合并慢性肝病及腹水患者的肾脏替代治疗:腹膜透析的作用
Perit Dial Int. 2008 Mar-Apr;28(2):113-7.

引用本文的文献

1
Reinfusion of ascites during hemodialysis as a treatment of massive refractory ascites and acute renal failure.血液透析期间腹水回输治疗大量难治性腹水和急性肾衰竭
Int J Nephrol Renovasc Dis. 2011;4:29-33. doi: 10.2147/IJNRD.S15792. Epub 2011 Feb 2.